Oliver is a Global Market Access Expert and head of Pricing & Access Team at PAREXEL. This team includes, Evidence Evaluation, HTA , Pric­ing, Health Economic Modelling and Payer Marketing. Oliver specialises in Market Access Strategic Planning and Payer Marketing - from early phase clinical trials through to in-market solutions. Previously Oliver worked as the Head of Market Access for Astellas, where he built and fully in­tegrated the Market Access Unit across the wider business: incorporat­ing HEOR, Government Affairs and Regional Market Access Specialists. Oliver has extensive experience in Product Commercialisation, Service Redesign, Pathway & Clinical Guideline Development, Payer Engagement and Payer Marketing. He has sat on the AWMSG Steering Group (HTA body for Wales) and has won awards for partnering with the Health­care Providers. His novel approaches to Service Redesign, including In­tegrated Care Pathways and Virtual Clinics ,have been showcased and replicated across a number of Health Economies in Europe.

John is currently Vice President, Global Health and Value for Pfizer’s Es­sential Health Business Unit, which has worldwide sales of more than $20B from a portfolio of over 700 molecules including biosimilars, sterile injectables and solid oral dosage forms. The portfolio is the result of Pfiz­er’s research and development as well as from the acquisitions of War­ner Lambert, Pharmacia and Upjohn, Wyeth and most recently Hospira. Pfizer is the world’s leading biosimilars company based on audited sales and its portfolio of biosimilar molecules is for the treatment of inflamma­tion, oncology and supportive care. Pfizer’s Global Health and Value team covers the functions of Pricing, Access, Reimbursement, Health Econom­ics, Outcomes Research and Real World Data. John has been with Pfizer for over 18 years in multiple roles of increasing responsibilities, the last three years in his current role. He has presented at several biosimilars conferences on the topic of pricing and access and in 2016 was a guest lecturer on the subject of HEOR at Kings College London as part of the International Federation of Association of Pharmaceutical Physicians.

Adam joined the Biogen biosimilars team in June 2015 responsible for Tenders & Contracting, Pricing Strategy & Governance, Value Demonstra­tion. He brings 14 years of market access experience, primarily from his time with Novo Nordisk in global, regional and affiliate roles including Head of Global Market Access and Market Access Europe. Later Adam was Global Market Access Director at Novartis responsible for Ilaris (canakinumab) where he worked closely with affiliates to understand contracting opportunities. Before joining Biogen, he was the Head of Global Market Access for CardioMetabolic at Takeda Pharmaceuticals.

Dr. Anne Marciniak is currently Senior Director, European HEOR with Al­lergan. She has 20-year experience in Market Access and Health Eco­nomics in the pharmaceutical industry, including Pfizer, Amgen and recently Daiichi-Sankyo. With her teams, she leads the Market Access strategy of multiple compounds in the European environment focusing on meeting the needs of payers at national, regional and local levels. She has hands-on experience in establishing strategies and leading their cross-functional execution, integrating all elements of product value in particular clinical and safety profile, health economics and price into the ‘value package’ to be submitted to stakeholders to ensure timely patients access. She believes that through engagement of all partners involved in the delivery of health care including payers the best value will be achieved for patients and the citizens ultimately financing care. She is a physician by training with an MPhil in Epidemiology and a PhD in Health Economics.

Anne-Toni is Head of Operations Global Payer Evidence and Pricing with AstraZeneca. She is responsible for Global Market Access strategy includ­ing Market Access Capability Development, Global Project & Business Strategy and Planning, Insight Strategy, Payer Excellence, RWE Alliance Management and Global Price and Evidence strategy. Prior to joining AstraZeneca she was a Senior Director for Baxter Healthcare, respon­sible for Government Relations, Market Access, Health Outcomes and Advocacy. Baxter’s portfolio includes pharmaceuticals biotechnology and medical devices. A pharmacologist by training, Anne-Toni has established several new businesses and functions; as a founding Board member she & the Board established the National Institute for Clinical Excellence (NICE) and her career has spanned pure research, regulatory affairs, sales & marketing, market access, communications, advocacy and gov­ernment & industry affairs.

Mona Khalid, BSc (Hons), MSc, PhD is Senior Director, Global Medical Affairs, GI Specialty therapy area and is Head of Evidence and Value Generation. She has extensive experience leading strategies for data generation in Health Economic and Outcomes Research for Health Tech­nology Assessments and Payers. Mona also has extensive experience in supporting development and launch activities for specialty care pharma­ceuticals. She has 13 years of experience in the pharmaceutical sector, mainly in Epidemiology, Biostatistics and Clinical Research. Mona holds a Bachelor in Science from the University of Waterloo and a PhD in Epide­miology from the University College London.

Since 6 years with Actavis (now Allergan), starting as Regional Direc­tor Central Europe. In 2011 joining the offices in Zug Switzerland as VP Supply Chain Management and since 2014 responsible for Market Access for Actavis International based in Switzerland. MSc in Pharmacy as background, having 25 years’ experience at several positions within the pharmaceutical industry. Starting in manufacturing and development within Yamanouchi Europe, followed by setting up marketing & sales channels in Central Europe the Middle East, AustralAsia and Africa. From 2002 – 2007 turn around management as CEO of Sicomed Romania, transforming a state owned company into a modern pharmaceutical com­pany. Sicomed was acquired end of 2005 by Zentiva.

Peter Rutherford qualified in Medicine in the UK and trained in Nephrolo­gy at the University of Newcastle and Yale University School of Medicine. He was a consultant physician in the UK as well as an NHS Hospital Medi­cal Director. In addition he was a clinical advisor for NICE in the clinical guidelines program. From 2007 until 2015 he was Medical Director for Europe, Middle East and Africa at Baxter Healthcare SA. Since 2015 Peter has been Vice President, Integrated Market Access at QuintilesIMS and is responsible for local market access activities, service improvement, pa­tient centric services and Medical Affairs – providing services for Pharma clients commercialising new products.

Bertrand joined Takeda in August 2013 as Head of Global Pricing. Moving from controller to consultant and business development manager for dif­ferent companies, he has built a broad experience in the pharmaceutical sector. With Takeda he joined a company that has been serving society with innovative medicines, helping patients reclaim valuable moments of life from illness. Now, with new healthcare solutions from prevention to care and cure, we are determined to help even more people enjoy their lives to the fullest.

Hassan Bruneo is a Senior Manager with Biogen and works in the EU+ Market Access and Strategic Pricing team. He joined the company in 2014 and is presently working in the European headquarter in Zug. He received his degree in biomedical engineering, from the Polytechnic of Milan, Italy in 2007. In the same year he started his business education in consultancy specializing in life sciences projects with public bodies (e.g. health performance improvement for public and private hospitals) and private institutions. His consulting work focused on designing com­mercial strategies (including international pricing and reimbursement), in order to maximize the monetization of the innovation for pharmaceuti­cal companies. His current experience in Biogen is focusing on keeping the current value of the MS portfolio maintaining an open dialogue with payers and external stakeholders in order to partner with policy makers to balance the need for feeding innovation and affordability. Hassan also contributed in training sessions, workshops and publications during his consultancy experience.

Dražen is qualified in Medicine with a postgraduate education in biosci­ence and a MBA degree. He has 15 years of experience in pharmaceuti­cal industry in almost all fields. Most of Dražen’s professional experience was in the field of oncology, which gave him a valuable experience of overcoming hurdles in access to innovation in demanding environment. He is currently Market Access Director responsible for leading Market Ac­cess team and establishing access cross-functional collaboration in Roche Croatia.

Graham is a motivating executive with a highly successful record of P&L accomplishments and leadership at the national and international level. He has expertise in personnel development, business development and operations management in complex and multicultural companies and settings. Graham has worked as Sales and Marketing Director in Astra­zeneca in Slovenia in 2003 and in 2005 he moved to Denmark to work for ALK-ABELLO HQ as the Global Marketing VP. Currently he is the EMEA President at Qualicaps in Spain where he is responsible for overseeing more than 450 employees in: Production, sales, marketing, customer service, medical, regulatory, research & development, HR, IT, and fi­nance departments. He also manages full P&L duties including B2B, Vaccines, Immunotherapy, Allergy, Asthma, Diagnostics, and injectable adrenalin devices.